The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) recommended that the live attenuated influenza vaccine (LAIV) not be used for the 2016-17 influenza season. Data have shown lower or poor effectiveness from LAIV from 2013 to 2016. Vaccine manufacturers had expected that LAIV would account for approximately eight percent of the total projected vaccine supply. About one third of children vaccinated against influenza receive the nasal spray. CDC is working with manufacturers to ensure an adequate vaccine supply for the upcoming flu season. Read the CDC release.